Article
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient.
American journal of hematology - 1 Dec 2006
Law Joanna K, Ali Jaber Al, Harrigan P Richard, Sherlock Christopher H, Savage Kerry J, Yoshida Eric M
Abstract excerpt
Hepatitis B reactivation is a well-known complication during or after chemotherapy in chronic hepatitis B (HBV) carriers. The current practice guidelines in Canada and the United States recommends patients receive antiviral prophylaxis prior to the onset of chemotherapy in chronic HBV carriers with lamivudine. We report a case of a 57-year-old man with follicular lymphoma on lamivudine prophylaxis and no clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.